心房颤动抗凝治疗进展  

Anticoagulation advance in atrial fibrillation

作　　者：薛利[1] 蔡衡[1] 

机构地区：[1]天津医科大学总医院心脏内科,天津300070

出　　处：《临床荟萃》2016年第1期14-18,共5页Clinical Focus

摘　　要：心房颤动是临床上最常见的心律失常,增加卒中风险。华法林抗凝效果虽已受到广泛的肯定,但同时存在出血风险、治疗窗狭窄、需要长期监测国际标准化比率以调整药量等缺点。新型口服抗凝药的应用如达比加群、利伐沙班、阿哌沙班可有效预防卒中及血栓栓塞。经皮左心耳封堵术亦可成为预防心房颤动血栓事件的有效替代治疗方式。Atrial fibrillation（AF）is one of the most common tachyarrhythmias in clinical practice.AF increases the risk of stroke.Warfarin has been proven effective.However,the high risk of bleeding,narrow therapeutic window,long term INR monitoring for proper adjustment of medication are the major drawbacks of this medicine.The novel oral anticoagulants（NOACs）such as dabigatran,rivaroxaban,and apixaban are effective and safe alternative to warfarin for the prevention of stroke and systemic emboli in patients with AF.Percutaneous left atrial appendage occlusion may be an effective alternative treatment for prevention of thromboembolic events in AF patients.

关 键 词：心房颤动 抗凝治疗 华法林 经皮左心耳封堵术 

分 类 号：R541.75[医药卫生—心血管疾病]